Benefits
Cardiovascular / Lipid Effects
Naringenin reduces hepatic lipogenesis and improves lipid profile in animal models. Modest human evidence. Mechanism: PPAR-alpha activation similar to fibrates.
Insulin Sensitivity / Glycemic Effects
Animal models show improved insulin sensitivity and reduced hepatic glucose production. Human clinical translation modest.
Antioxidant Activity
Direct free radical scavenging plus Nrf2 pathway activation. Component of cardiovascular and longevity supplementation.
Anti-Inflammatory Effects
Reduces inflammatory cytokine production, modulates NF-κB pathway. Modest anti-inflammatory profile.
Hepatitis C Antiviral Research (Preliminary)
Some research shows naringenin reduces hepatitis C virus secretion in vitro. Theoretical antiviral applications; clinical translation pending.
Mechanism of action
PPAR-Alpha Activation
Naringenin activates peroxisome proliferator-activated receptor alpha (PPAR-alpha) — same nuclear receptor target as fibrate drugs (gemfibrozil, fenofibrate). Reduces lipogenesis, increases fatty acid oxidation.
AMPK Activation
Activates AMP-activated protein kinase — improving glucose uptake, fat oxidation, reduced lipogenesis. Same target as metformin and exercise.
NARINGIN VS NARINGENIN DISTINCTION (Grapefruit Drug Interaction)
CRITICAL: NARINGIN (the glycoside form, abundant in grapefruit) is responsible for the famous grapefruit-drug interaction via inhibition of intestinal CYP3A4 and OATP transporters. NARINGENIN (the aglycone metabolite formed by gut bacteria) has DIFFERENT pharmacology and likely doesn't replicate the full grapefruit effect. Supplemental naringenin should not produce grapefruit-juice level drug interactions, but data is limited.
Antioxidant Pathway Activation
Direct radical scavenging plus Nrf2 transcription factor activation upregulating endogenous antioxidant enzymes.
Clinical trials
Multiple animal studies of naringenin for hyperlipidemia and metabolic syndrome.
Animal models predominantly.
Significant improvements in lipid profile, glucose, insulin sensitivity in animals. Human trials limited and lower quality.
Pharmacokinetic studies establishing naringenin oral bioavailability and metabolism.
Healthy adults.
Naringenin oral bioavailability low (~5-15%); rapidly metabolized to glucuronides and sulfates. Plasma concentrations achievable with supplementation may be insufficient for some in vitro mechanisms.